Concerns Mount Over FDA's Proposed Vaccine Policy Changes

A recent internal memo from Dr. Vinay Prasad, the director of the FDA’s vaccine division, has sparked significant backlash from 12 former Food and Drug Administration (FDA) commissioners. These former leaders, who served under both Republican and Democratic administrations, expressed alarm over proposed changes to vaccine regulation that they argue could jeopardize public health. The memo, which was leaked to The New York Times, suggests a reevaluation of vaccine safety standards following claims that 10 childhood deaths were linked to COVID-19 vaccinations.

New York TimesFiercePharmaSTAT (News)New York Times

In the memo dated November 28, 2025, Prasad outlined a series of sweeping changes intended to overhaul how vaccines are regulated and approved. Among these proposals are stricter requirements for vaccine studies, including the need for larger trials that encompass all demographic subgroups, such as pregnant women. Prasad also indicated a potential shift away from using immunogenicity data—typically used to assess vaccine effectiveness—toward requiring more extensive clinical endpoint studies. This could significantly delay the development of vaccines, particularly those needed to respond to rapidly evolving respiratory viruses.

New York Times

The former commissioners, including notable figures like Scott Gottlieb and Robert Califf, criticized the proposed guidelines as a drastic departure from established FDA practices. They argued that the changes are based on a selective interpretation of evidence and lack transparency. In their article published in The New England Journal of Medicine, they stated, “If the goal is to rebuild confidence, the answer is not to toss aside the basic rules of science.” They emphasized the importance of open deliberation and rigorous scientific inquiry in maintaining public trust in vaccine safety.

CNN

The former commissioners raised concerns that the FDA's new framework could disadvantage vulnerable populations, including those with weakened immune systems. They pointed out that the memo did not provide sufficient evidence to support the claims linking the deaths of children to the vaccines, nor did it explain the methodology behind these assertions. They warned that such unilateral decision-making undermines the agency's credibility and could lead to significant public health risks.

STAT (News)

In response to the criticism, an FDA spokesperson indicated that the agency would soon release documents detailing the new framework and the data supporting the claims made in Prasad's memo. They asserted that the changes are necessary for ensuring evidence-based science in vaccine approvals. However, the former commissioners cautioned that these changes could suppress innovation and competition in vaccine development, ultimately harming public health.

CNNFiercePharmaSTAT (News)New York Times

The controversy surrounding the FDA's proposed changes reflects broader tensions within the agency, particularly under the leadership of Health Secretary Robert F. Kennedy Jr. Critics argue that the current administration's approach to vaccine policy is haphazard and lacks the necessary scientific rigor. As the FDA prepares to implement these changes, the implications for vaccine access and public health remain a pressing concern.

CNN

• “We are deeply concerned by sweeping new FDA assertions about vaccine safety and proposals that would undermine a regulatory model designed to ensure that vaccines are safe, effective, and available when the public needs them most,” — Former FDA Commissioners

CNN

• “The proposed guidelines would dramatically change vaccine regulation on the basis of a reinterpretation of selective evidence and by a process that breaks sharply with the norms that have anchored the FDA’s globally respected scientific integrity,” — Former FDA Commissioners

FiercePharma

• “Demands for ideological alignment as a condition of employment are irreconcilable with an agency whose strength is the pluralism of its expert views,” — Former FDA Commissioners

FiercePharma

The ongoing debate over the FDA's vaccine policy changes highlights the critical balance between regulatory oversight and public health imperatives, a discussion that is likely to evolve as new information emerges.

CNN